DEFA14A: Black Diamond Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.

Summary

• Black Diamond Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.
• Stockholders can vote virtually during the meeting or in advance by June 11, 2025.
• The meeting will include the election of three Class II Directors: Ali Behbahani, Garry Menzel, and Samarth Kulkarni.
• Stockholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Proxy materials are available online, and stockholders can request a free paper or email copy before May 29, 2025.

Sentiment

Score: 7

Explanation: The document is a routine announcement with no particularly positive or negative implications. It's a necessary part of corporate governance.

Positives

• The company is providing multiple avenues for stockholders to access proxy materials and vote, including online access and options to request physical or electronic copies.
• The virtual format of the annual meeting allows for broader participation from stockholders.

Future Outlook

The board will consider any other business that may properly come before the meeting.

Industry Context

This is a standard annual meeting announcement, a routine part of corporate governance for publicly traded companies.

Stakeholder Impact

• Stockholders have the opportunity to vote on key company matters.
• The outcome of the votes will influence the company's direction and governance.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the annual meeting on June 12, 2025.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Vote, Black Diamond Therapeutics, Directors, PricewaterhouseCoopers, Auditor